Psilocybin-assisted neurofeedback for the improvement of executive functions: a semi-naturalistic-lab feasibility study
This semi-naturalistic feasibility study found that psilocybin-assisted frontal-midline theta neurofeedback is practicable without psychological support and produced a trend-level increase in frontal-midline theta alongside significant self-reported improvements in everyday executive functions (working memory, shifting, monitoring, inhibition). However, no objective task-based gains were observed, indicating the need for larger randomised trials with regular sessions and active controls to confirm efficacy and specificity.
Authors
- Enriquez-Geppert, S,, Krc, J.
- O'Higgins, F.
- Lietz, M. P.
Published
Abstract
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting treatment and training responsiveness. In this pioneering study, we evaluated the feasibility and preliminary efficacy of psilocybin-assisted frontal-midline theta neurofeedback (NF), a neuromodulation technique leveraging neuroplasticity, to improve executive functions (EFs). 37 eligible participants were randomised into an experimental (n=18) and a passive control group (n=19). The experimental group underwent three microdose sessions and then three psilocybin-assisted NF sessions, without requiring psychological support, demonstrating the approach’s feasibility. NF learning showed a statistical trend with large effect size for increases in frontal-midline theta from session-to-session with a large effect size, and non-significant but medium effect size dynamical changes within sessions. Placebo effects were consistent across groups, with no tasks-based EFs improvements, but significant self-reported gains in daily EFs -working memory, shifting, monitoring and inhibition- showing medium and high effect sizes. The experimental group’s significant gains in their key training goals underscored the approach’s external relevance. A thorough study with regular sessions and an active control group is crucial to evaluate EFs improvement and their specificity in future. Psilocybin-enhanced NF could offer significant, lasting benefits across diagnoses, improving daily functioning.
Research Summary of 'Psilocybin-assisted neurofeedback for the improvement of executive functions: a semi-naturalistic-lab feasibility study'
Introduction
Executive function (EF) deficits are a transdiagnostic feature across psychiatric disorders and substantially impair daily functioning and recovery. Fronto‑cingulo‑parietal networks, and specifically frontal‑midline (fm) theta oscillations thought to originate in midcingulate and dorsolateral prefrontal cortices, have been linked to successful EF performance; the inability to upregulate fm‑theta correlates with poorer task outcomes. Neurofeedback (NF) targeting fm‑theta can enable participants to learn self‑regulation of this neural signal and has shown medium‑sized benefits for components of EF such as working memory updating, but responsiveness to NF varies and a subgroup of “non‑responders” limits clinical utility. Impaired neuroplasticity has been proposed as one factor reducing NF learning in psychiatric populations. Enriquez‑Geppert and colleagues set out to examine the feasibility and initial effects of combining a neuroplasticity‑promoting pharmacological agent, psilocybin (delivered as repeated microdoses), with fm‑theta NF. The study aimed to test whether a brief protocol—one week of dose adjustment followed by three psilocybin‑assisted NF sessions—was practical in a semi‑naturalistic lab setting, to assess effects on EEG fm‑theta self‑regulation, on objective laboratory EF tasks, and on self‑reported EF in daily life, and to evaluate expectancy/placebo proxies and participant‑centred priority outcomes.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- APA Citation
Enriquez-Geppert, S., Krc, J., O'Higgins, F., & Lietz, M. P. (2023). Psilocybin-assisted neurofeedback for the improvement of executive functions: a semi-naturalistic-lab feasibility study. https://doi.org/10.31234/osf.io/jqasf
References (25)
Papers cited by this study that are also in Blossom
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Kopra, E., Cleare, A. J., Rucker, J. et al. · Journal of Affective Disorders (2022)
Vargas, M. V., Dunlap, L. E., Dong, C. et al. · Science (2023)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
Moliner, R., Girych, M., Brunello, C. A. et al. · Nature Neuroscience (2023)
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · ACS Pharmacology and Translational Science (2020)
Glazer', J., Murray, C. H., Nusslock', R. et al. · Neuropsychopharmacology (2022)
Show all 25 referencesShow fewer
Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)
Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Holze, F., Ley, L., Müller, F. et al. · Neuropsychopharmacology (2022)
McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Kiilerich, K. F., Lorenz, J., Scharff, M. B. et al. · Molecular Psychiatry (2023)
Perry, C. M., Malina, M. · Psychopharmacology (2021)
Sanz, C., Cavanna, F., Muller, S. et al. · Psychopharmacology (2022)
Van Elk, M., Fejer, G., Lempe, P. et al. · Psychopharmacology (2021)
Holze, F., Becker, A. M., Kolaczynska, K. E. et al. · Clinical Pharmacology and Therapeutics (2022)
Luethi, D., Hoener, M. C., Krähenbühl, S. et al. · Biochemical Pharmacology (2019)
Vizeli, P., Straumann, I., Holze, F. et al. · Scientific Reports (2021)
Fadiman, J., Korb, S. · Journal of Psychoactive Drugs (2019)
Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.